New heart attack data boost AZ’s Brilinta
AstraZeneca, Brilinta, cardiology, ESC2017, European Society of Cardiology
0 Comment
A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.